<p>Research shows that patients using Novo Nordisk's weight loss drug Wegovy in combination with Eli Lilly's experimental drug bimagrumab can effectively maintain muscle mass while losing weight. According to results announced at the American Diabetes Association annual meeting held in Chicago on Monday, patients on the combination therapy lost 22.1% of their body weight over 48 weeks, with 92.8% of that being fat loss. These findings provide a potential solution to the muscle loss issue associated with currently popular obesity medications. Researchers are also exploring other drug combinations, but these combinations may carry a higher risk of side effects. Eli Lilly is currently up over 3%</p>

<p>Research shows that Eli Lilly's drug bimagrumab, when used in combination with Novo Nordisk's weight loss drug Wegovy, can effectively reduce muscle loss. According to results announced at the American Diabetes Association annual meeting, patients lost 22.1% of their body weight over 48 weeks, with 92.8% of that being fat loss. This study provides a potential solution to the muscle loss issue associated with obesity medications. Eli Lilly's stock price rose by more than 3%</p>

礼来药物与 Wegovy 联用可减少肌肉流失